DSCAM-AS1 and breast carcinoma: While ER-positive breast cancers typically result in better clinical outcomes23, among the luminal breast cancers, DSCAM-AS1 is expressed significantly higher in luminal B, a clinical subtype containing most of the clinically aggressive ER-positive breast cancers22, 23 (Fig. 3c).